MXPA02006055A - Agentes liberadores de hidroxido como incrementadores de penetracion en la piel. - Google Patents

Agentes liberadores de hidroxido como incrementadores de penetracion en la piel.

Info

Publication number
MXPA02006055A
MXPA02006055A MXPA02006055A MXPA02006055A MXPA02006055A MX PA02006055 A MXPA02006055 A MX PA02006055A MX PA02006055 A MXPA02006055 A MX PA02006055A MX PA02006055 A MXPA02006055 A MX PA02006055A MX PA02006055 A MXPA02006055 A MX PA02006055A
Authority
MX
Mexico
Prior art keywords
hydroxidereleasing
agents
permeation enhancers
skin permeation
skin
Prior art date
Application number
MXPA02006055A
Other languages
English (en)
Inventor
Russell Macy
Original Assignee
Dermatrends Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/738,395 external-priority patent/US6719997B2/en
Priority claimed from US09/738,410 external-priority patent/US6586000B2/en
Application filed by Dermatrends Inc filed Critical Dermatrends Inc
Publication of MXPA02006055A publication Critical patent/MXPA02006055A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)

Abstract

Se provee un metodo para incrementar la permeabilidad de la piel o tejido de la mucosa a agentes farmacologicamente o cosmeceuticamente activos administrados por via topica o transdermica; el metodo implica el uso de una cantidad especificada de un agente liberador de hidroxido, la cantidad optimizada para incrementar el flujo del agente activo a traves de una superficie del cuerpo mientras se reduce al minimo la probabilidad de dano, irritacion o sensibilizacion de la piel; tambien proveen formulaciones aplicadas por via topica y los dispositivos de surtido de farmaco que emplean agentes liberadores de hidroxido como incrementadores de penetracion.
MXPA02006055A 1999-12-16 2000-12-15 Agentes liberadores de hidroxido como incrementadores de penetracion en la piel. MXPA02006055A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US46509899A 1999-12-16 1999-12-16
US56988900A 2000-05-11 2000-05-11
US60789200A 2000-06-30 2000-06-30
US09/738,395 US6719997B2 (en) 2000-06-30 2000-12-14 Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
US09/738,410 US6586000B2 (en) 1999-12-16 2000-12-14 Hydroxide-releasing agents as skin permeation enhancers
PCT/US2000/034483 WO2001043775A2 (en) 1999-12-16 2000-12-15 Hydroxide-releasing agents as skin permeation enhancers

Publications (1)

Publication Number Publication Date
MXPA02006055A true MXPA02006055A (es) 2004-08-23

Family

ID=27541690

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02006055A MXPA02006055A (es) 1999-12-16 2000-12-15 Agentes liberadores de hidroxido como incrementadores de penetracion en la piel.

Country Status (12)

Country Link
EP (1) EP1239845B1 (es)
JP (1) JP2004500360A (es)
CN (1) CN100482216C (es)
AT (1) ATE290856T1 (es)
AU (1) AU778475B2 (es)
BR (1) BR0016402A (es)
CA (1) CA2393762A1 (es)
DE (1) DE60018797T2 (es)
ES (1) ES2239057T3 (es)
MX (1) MXPA02006055A (es)
NZ (1) NZ520015A (es)
WO (1) WO2001043775A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030059450A1 (en) 2001-09-24 2003-03-27 Maibach Howard I. Method and topical formulation for treating skin conditions associated with aging
US6846837B2 (en) 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
US6821523B2 (en) 2002-06-21 2004-11-23 Dermatrends, Inc. Topical administration of pharmacologically active bases in the treatment of warts
US6943197B2 (en) 2002-06-21 2005-09-13 Howard I. Maibach Topical administration of pharmacologically active bases in the treatment of inflammatory dermatoses
DE60305068T2 (de) * 2002-12-18 2007-01-11 Laboratoires Besins International Behandlung von mastalgie mit 4-hydroxy-tamoxifen
MXPA05010597A (es) 2003-04-01 2006-03-09 Lab Besins Internat Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi.
AU2004281766A1 (en) * 2003-10-14 2005-04-28 Dermatrends, Inc. Enhancing transdermal administration of hydrophilic drugs
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20080138390A1 (en) * 2004-04-07 2008-06-12 Tsung-Min Hsu Transdermal Delivery System For Use With Basic Permeation Enhancers
JP5148271B2 (ja) * 2004-06-02 2013-02-20 ニューロジズエックス，インコーポレーテッド 疼痛処置のためのカプサイシノイド、局所麻酔薬および／または鎮痒薬を含有する処方物
US20060263421A1 (en) * 2005-05-18 2006-11-23 Abeille Pharmaceuticals Inc Transdermal Method and Patch for Nausea
CA2548864C (en) * 2005-06-06 2012-12-11 Nitto Denko Corporation Percutaneous absorption-type pharmaceutical preparation
EP1731143B1 (en) * 2005-06-06 2008-11-26 Nitto Denko Corporation Percutaneous absorption-type pharmaceutical preparation using a metal chloride, preferably sodium chloride, for preventing cohesive failure
NZ552816A (en) * 2007-01-24 2009-05-31 Bomac Research Ltd Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof
DE102007006244B4 (de) * 2007-02-08 2012-03-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System zur Verabreichung wasserlöslicher Wirkstoffe
CN102088935B (zh) 2008-03-31 2015-07-15 日东电工株式会社 透膜物递送系统
CN104825445A (zh) 2009-04-22 2015-08-12 墨卡托医疗系统公司 局部血管递送胍乙啶在治疗高血压中的用途
CN101532992B (zh) * 2009-04-23 2011-09-28 复旦大学附属中山医院 一种高效液相色谱检测血液中吡啶硫胺素的方法
DE102009022915A1 (de) * 2009-05-27 2010-12-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit gesteuertem Wirkstofffluss
JP2012092022A (ja) * 2010-10-25 2012-05-17 Tokuhon Corp 皮膚外用貼付剤
US20140037710A1 (en) 2011-04-18 2014-02-06 Hisamitsu Pharmaceutical Co., Inc. Method for producing patch, and patch
AU2012325801B2 (en) * 2011-10-19 2016-05-12 Mercator Medsystems, Inc. Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation
CN103695931B (zh) * 2013-11-29 2016-08-24 明光市留香泵业有限公司 一种水溶性金属短期防锈液及其制备方法
JP7030517B2 (ja) 2015-01-07 2022-03-07 トライジェミナ， インコーポレイテッド マグネシウム含有オキシトシン製剤および使用の方法
CA3114750A1 (en) 2018-10-09 2020-04-16 University Of Rochester Treatment of vulvovaginal disorders
CN110692647A (zh) * 2019-05-06 2020-01-17 科瑞百奥泰州生物技术有限公司 一种适用于同种异体和异种异体组织及组织工程医疗器械的灭菌液和灭菌方法
WO2021211558A1 (en) * 2020-04-14 2021-10-21 Glanis Pharmaceutical Inc. Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
FR3111796B1 (fr) * 2020-06-26 2022-08-12 Oreal Procédé de traitement cosmétique des matières kératiniques comprenant l’application d’une composition de terre rare et l’application d’un patch comprenant une composition comprenant un actif particulier

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5998014A (ja) * 1982-11-29 1984-06-06 Taisho Pharmaceut Co Ltd 鎮痒剤
JPH0794394B2 (ja) * 1986-12-24 1995-10-11 前田薬品工業株式会社 消炎鎮痛外用貼付剤
JP2933944B2 (ja) * 1989-03-29 1999-08-16 日東電工株式会社 医療用貼付剤
EP0387751B1 (en) * 1989-03-15 1994-06-08 Nitto Denko Corporation Medicated plasters
JP2764183B2 (ja) * 1989-05-31 1998-06-11 日東電工株式会社 医療用貼付剤
JPH02243626A (ja) * 1989-03-15 1990-09-27 Nitto Denko Corp 医療用貼付剤
US5462744A (en) * 1989-12-01 1995-10-31 Boehringer Ingelheim Kg Transdermal system for the administration of pharmacological compounds under pH-controlled conditions
KR950007098B1 (ko) * 1992-08-18 1995-06-30 유우껭 가이샤 도또 물리적 경피 흡수촉진제 및 이것을 함유하는 첩부제
JPH0692843A (ja) * 1992-09-10 1994-04-05 Sekisui Chem Co Ltd 経皮吸収貼付剤
IL109036A (en) * 1993-03-19 1998-12-27 Cellegy Pharamaceuticals Inc Preparations for detachment of the epithelial barrier function and use of means for the preparation of such preparations
US5498417A (en) * 1994-05-12 1996-03-12 Coating Sciences, Inc. Transdermal delivery of appetite suppressant drug
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
GB2290964A (en) * 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
TW411277B (en) * 1996-05-13 2000-11-11 Hisamitsu Pharmaceutical Co Percutaneous tape preparation containing fentanyl

Also Published As

Publication number Publication date
DE60018797T2 (de) 2006-04-13
BR0016402A (pt) 2003-05-27
CA2393762A1 (en) 2001-06-21
JP2004500360A (ja) 2004-01-08
AU2279101A (en) 2001-06-25
EP1239845B1 (en) 2005-03-16
AU778475B2 (en) 2004-12-09
WO2001043775A3 (en) 2002-02-21
CN1434705A (zh) 2003-08-06
DE60018797D1 (de) 2005-04-21
NZ520015A (en) 2003-03-28
EP1239845A2 (en) 2002-09-18
WO2001043775A2 (en) 2001-06-21
ES2239057T3 (es) 2005-09-16
CN100482216C (zh) 2009-04-29
ATE290856T1 (de) 2005-04-15

Similar Documents

Publication Publication Date Title
MXPA02006055A (es) Agentes liberadores de hidroxido como incrementadores de penetracion en la piel.
ES2275716T3 (es) Composicion farmaceutica de liberacion transdermica.
WO2000038625A3 (en) Facial tissue composition and method of use for sequestration of nasal secretion skin irritants
MXPA02002895A (es) Tratamiento topico de infecciones por estreptococcus.
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
CA2341063A1 (en) Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
UA83320C2 (ru) Таблетка для рассасывания, содержащая октенидин и предназначенная для лечения воспалительных заболеваний полости рта и глотки
AU2001236886A1 (en) Use of relaxin to treat diseases related to vasoconstriction
MXPA04000654A (es) Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
CY1107465T1 (el) Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων
ATE251901T1 (de) Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson
NZ507203A (en) Use of dexmedetomidine for ICU sedation
PT904067E (pt) Dextrometorfan como agente antitussico administrado transdermicamente
NZ516765A (en) Topical formulations comprising skin penetration agents and the use thereof
GEP20043231B (en) Resorcinol Composition
SE9900177D0 (sv) Vårtmedel
HUP0102191A2 (hu) Oxazolidinonszármazékok helyileg történő alkalmazása transzdermális gyógyszerkészítményekben
DK0705085T3 (da) Molykylært transdermalt transportsystem
ZA988820B (en) Use of delta-aminolaevulinic acid for the preparation of a topical medicament for the integral diagnosis and/or therapy of tumours in hollow organs
DE60130253D1 (de) Zusammensetzungen zur verhinderung der adhäsion
CA2306772A1 (en) Use of c18 to c26 aliphatic alcohols for the manufacture of a medicament in the treatment of hyperproliferative skin disorders

Legal Events

Date Code Title Description
FG Grant or registration